Go Back

EANM Procedure Guidelines in Oncology

On this page you will find links to some European Association of Nuclear Medicine (EANM) Procedure Guidelines relating to Oncology applications. The aim of these documents is to provide general information about the clinical procedures described.

They are categorized in clinical applications. Please follow the links below to the desired applications.

The purpose of this document is to provide general information about bone scintigraphy in oncology. The corresponding guidelines from the Society of Nuclear Medicine (SNM) have been taken into consideration, reviewed and partially integrated with this text. Bone scintigraphy is an highly sensitive method for demonstrating disease in bone. Phosphate analogues can be labelled with 99mTc and are used for bone imaging because of their good localisation in the skeleton and rapid clearance from soft tissues.


The aim of this document is to provide general information about breast scintigraphy in patients with known or suspected breast cancer. The corresponding guidelines of the Society of Nuclear
Medicine (SNM) have been taken into consideration and partially integrated with the present text. It describes only the 99mTc-SestaMIBI(2-methoxyisobutiylisonitrile) and the 99mTc-Tetrofosmin (1,2-bis bis(2-ethoxy-ethylphosphine)ethane) breast scintigraphy protocols used in the current clinical routine.


The aim of this document is to provide general information about 67Ga scintigraphy in oncology. 67Ga imaging of neoplastic disease has shown the greatest utility in imaging lymphomas but it can also be used for other tumours.


The aim of this document is to provide general information about MIBG scintigraphy in cancer patients. This guideline describes the MIBG scintigraphy protocol currently used in the clinical routine, but does not include all existing procedures for neuroendocrine tumours. MIBG scintigraphy is used to image tumours of neuroendocrine origin, particularly those of the sympathoadrenal system (phaeochromocytomas, paragangliomas and neuroblastomas), although other neuroendocrine tumours (carcinoids, medullary thyroid carcinoma, etc.) are also visualised.


This document provides general information about somatostatin receptor scintigraphy with 111In-pentetreotide. Somatostatin receptors have been identified on many cells of neuroendocrine origin; additionally, several non-neural and non-endocrine cells sometimes display somatostatin receptors with various degrees of density. Consequently, tumours deriving from cell types expressing somatostatin receptors may be imaged by somatostatin receptor scintigraphy.


This document provides general information about scintigraphic detection of sentinel node in breast cancer. Sentinel lymph node biopsy (SNB) is a minimally invasive procedure used to accurately stage nodal basins at risk for harboring occult metastases in patients without clinical spread of the disease. Lymphoscintigraphy (LS) allows the surgeon to easily identify and biopsy the sentinel lymph node. The radiopharmaceuticals commonly employed for LS are 99mTc-sulphur colloid, 99mTc-nanocolloid, 99mTc-antimony trisulphide.


The document was prepared by a multidisciplinary, international working group comprising scientists and clinicians from many different European and other countries, all with sub-speciality expertise within the different fields involved in sentinel node diagnostics. It outlines recommendations for sentinel node diagnostics for optimal staging in melanoma patients without known clinical dissemination. The radiopharmaceuticals commonly used are 99mTc-labelled colloids as for LS in breast cancer.


These guidelines were prepared by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the EANM Oncology Committee and the Sentinel European Node Trial Committee. The aim of this review is to provide evidence-based guidelines for the use of sentinel node biopsy as a staging tool in patients with early OSCC. 99mTc-labelled colloid pharmaceuticals are used as for LS in breast cancer and melanoma.


The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG).The Procedure Guidelines for Tumour Imaging with FDG PET/CT of the Society of Nuclear Medicine (SNM), the German Guidelines for FDG-PET/CT in Oncology, the quality control/assurance procedures used in the UK for lymphoma/head and neck cancer studies and the Netherlands protocol for standardisation of quantitative whole-body FDG PET/CT studies have been integrated in the present guideline.